MorphoSys AG announced today the launch of a novel antibody optimization platform called arYla. The company plans to use arYla to accelerate antibody optimization, with the goal of generating superior therapeutic and diagnostic candidates faster and more cost-effectively than is currently possible. arYla will be used to optimize a range of properties critical to the successful development of a therapeutic or diagnostic antibody. The arYla technology results from the combined technology platforms of MorphoSys and recently acquired Sloning BioTechnology.
"We see many therapeutic and diagnostic antibody programs in our industry in which shortcomings in the antibody hinder the development of a successful product," commented Dr Simon Moroney, Chief Executive Officer of MorphoSys AG. "arYla gives us a unique and proprietary means of optimizing antibody properties, which we expect to lead to better products - both therapeutics and diagnostics - faster than is possible today. We intend to apply the technology in our own programs and within existing as well as new partnerships, and are already seeing considerable interest in the pharmaceutical industry."
With the arYla technology, MorphoSys combines more than 15 years of experience in design and selection of therapeutic antibodies with the unique library synthesis capabilities acquired with Sloning in October 2010. arYla brings significant advantages to antibody optimization especially in terms of speed and flexibility.
The new technology enables individualized antibody libraries to be made with unprecedented speed and precision. arYla will be used to make diverse, customized sub-libraries based on an existing lead compound, incorporating many millions of pre-defined variations at precisely determined sites within the antibody structure. In this way, antibodies optimized for a multitude of properties, including affinity, specificity, humanness, solubility, stability, production yield and others, can rapidly be identified.
MorphoSys AG
